Abstract
This study investigated the functional interplay between vascular endothelial growth factor (VEGF) and metalloproteinases (MMPs) in ovarian carcinomas. Levels of MMP9 (pro and activated form) and proMMP2 in ascites correlated with VEGF and with the ascitic volume in nude mice bearing human ovarian carcinoma xenografts (HOC22 and HOC8). The MMP inhibitor batimastat (BB-94) reduced VEGF release and ascitic fluid formation. Exogenous, activated MMP9, and, to a lesser extent, MMP2, increased VEGF release by SKOV3 and OVCAR3 ovarian carcinoma cells. The effect was dose and time dependent and inhibited by BB-94. MMP9-released VEGF was biologically active, because it induced endothelial cell motility, and its activity was prevented by the VEGF inhibitor SU5416. Our results indicate that MMPs, mainly MMP9, play a role in the release of biologically active VEGF and consequently in the formation of ascites.
| Original language | English |
|---|---|
| Pages (from-to) | 5224-5229 |
| Number of pages | 6 |
| Journal | Cancer Research |
| Volume | 63 |
| Issue number | 17 |
| Publication status | Published - Sep 1 2003 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells : Implications for ascites formation. / Belotti, Dorina; Paganoni, Paola; Manenti, Luigi; Garofalo, Angela; Marchini, Sergio; Taraboletti, Giulia; Giavazzi, Raffaella.
In: Cancer Research, Vol. 63, No. 17, 01.09.2003, p. 5224-5229.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells
T2 - Implications for ascites formation
AU - Belotti, Dorina
AU - Paganoni, Paola
AU - Manenti, Luigi
AU - Garofalo, Angela
AU - Marchini, Sergio
AU - Taraboletti, Giulia
AU - Giavazzi, Raffaella
PY - 2003/9/1
Y1 - 2003/9/1
N2 - This study investigated the functional interplay between vascular endothelial growth factor (VEGF) and metalloproteinases (MMPs) in ovarian carcinomas. Levels of MMP9 (pro and activated form) and proMMP2 in ascites correlated with VEGF and with the ascitic volume in nude mice bearing human ovarian carcinoma xenografts (HOC22 and HOC8). The MMP inhibitor batimastat (BB-94) reduced VEGF release and ascitic fluid formation. Exogenous, activated MMP9, and, to a lesser extent, MMP2, increased VEGF release by SKOV3 and OVCAR3 ovarian carcinoma cells. The effect was dose and time dependent and inhibited by BB-94. MMP9-released VEGF was biologically active, because it induced endothelial cell motility, and its activity was prevented by the VEGF inhibitor SU5416. Our results indicate that MMPs, mainly MMP9, play a role in the release of biologically active VEGF and consequently in the formation of ascites.
AB - This study investigated the functional interplay between vascular endothelial growth factor (VEGF) and metalloproteinases (MMPs) in ovarian carcinomas. Levels of MMP9 (pro and activated form) and proMMP2 in ascites correlated with VEGF and with the ascitic volume in nude mice bearing human ovarian carcinoma xenografts (HOC22 and HOC8). The MMP inhibitor batimastat (BB-94) reduced VEGF release and ascitic fluid formation. Exogenous, activated MMP9, and, to a lesser extent, MMP2, increased VEGF release by SKOV3 and OVCAR3 ovarian carcinoma cells. The effect was dose and time dependent and inhibited by BB-94. MMP9-released VEGF was biologically active, because it induced endothelial cell motility, and its activity was prevented by the VEGF inhibitor SU5416. Our results indicate that MMPs, mainly MMP9, play a role in the release of biologically active VEGF and consequently in the formation of ascites.
UR - http://www.scopus.com/inward/record.url?scp=0141482154&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141482154&partnerID=8YFLogxK
M3 - Article
VL - 63
SP - 5224
EP - 5229
JO - Journal of Cancer Research
JF - Journal of Cancer Research
SN - 0008-5472
IS - 17
ER -